Seeking Alpha: With Demonstrated Execution, Will Aviva Finally Get Some Love?

I can't say my bullish call on British insurance company Aviva plc (NYSE:AV) has been a good one, as the shares are down about 15% from my June 2015 article and only about half of that decline can be attributed to currency. While premium growth in the non-life business has been a little pokey, the life business has grown pretty nicely and the company surprised everybody with a stronger capital position vis-a-vis Solvency II.

Looking ahead, management still has to prove that Aviva can wring operational synergies from the Friends acquisition and take advantage of what management believes will be a growth market in UK savers and a significant cross-selling opportunity. At the same time, delivering on the growth potential of markets like Poland and Turkey is important. I continue to believe that Aviva is a significantly underrated company, and with worries about its capital position likely to diminish, a fair value of nearly $18 makes this a stock to consider.

Continue here:
With Demonstrated Execution, Will Aviva Finally Get Some Love?

Seeking Alpha: Defensive Allianz Not Feeling The Love

Germany-based multinational insurance giant Allianz (OTCQX:AZSEY) has amply demonstrated that it is a well-run insurer with strong underwriting policies and capital allocation discipline. Unfortunately, it's a lot of what investors don't seem to want these days - it's focused on slower-growing Western European markets when investors want to tap the growth in Latin America and Asia, it's defensive when investors want offense, and it hasn't been particularly aggressive in keeping up with AXA (OTCQX:AXAHY) or Aegon (AEG) in terms of new product development. Although I do like AXA more, I think the market is underestimating the value of this lagging giant today.

Follow this link for more:
Defensive Allianz Not Feeling The Love